Xvivo Perfusion Ab Stock Probability of Future Pink Sheet Price Finishing Over 42.88
| XVIPF Stock | USD 41.23 0.77 1.83% |
Xvivo |
Xvivo Perfusion Target Price Odds to finish over 42.88
The tendency of Xvivo Pink Sheet price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move over $ 42.88 or more in 90 days |
| 41.23 | 90 days | 42.88 | about 86.14 |
Based on a normal probability distribution, the odds of Xvivo Perfusion to move over $ 42.88 or more in 90 days from now is about 86.14 (This Xvivo Perfusion AB probability density function shows the probability of Xvivo Pink Sheet to fall within a particular range of prices over 90 days) . Probability of Xvivo Perfusion AB price to stay between its current price of $ 41.23 and $ 42.88 at the end of the 90-day period is about 7.95 .
Assuming the 90 days horizon Xvivo Perfusion has a beta of 0.22. This entails as returns on the market go up, Xvivo Perfusion average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Xvivo Perfusion AB will be expected to be much smaller as well. Additionally Xvivo Perfusion AB has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Xvivo Perfusion Price Density |
| Price |
Predictive Modules for Xvivo Perfusion
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Xvivo Perfusion AB. Regardless of method or technology, however, to accurately forecast the pink sheet market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the pink sheet market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Xvivo Perfusion Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Xvivo Perfusion is not an exception. The market had few large corrections towards the Xvivo Perfusion's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Xvivo Perfusion AB, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Xvivo Perfusion within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.26 | |
β | Beta against Dow Jones | 0.22 | |
σ | Overall volatility | 3.47 | |
Ir | Information ratio | -0.18 |
Xvivo Perfusion Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Xvivo Perfusion for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Xvivo Perfusion AB can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Xvivo Perfusion AB generated a negative expected return over the last 90 days | |
| Xvivo Perfusion AB has accumulated about 22.66 M in cash with (12.06 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.86. | |
| Roughly 12.0% of the company outstanding shares are owned by insiders | |
| Latest headline from MacroaxisInsider: Acquisition by Hankey Bret of 1063830 shares of Bone Biologics subject to Rule 16b-3 |
Xvivo Perfusion Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Xvivo Pink Sheet often depends not only on the future outlook of the current and potential Xvivo Perfusion's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Xvivo Perfusion's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 29.5 M |
Xvivo Perfusion Technical Analysis
Xvivo Perfusion's future price can be derived by breaking down and analyzing its technical indicators over time. Xvivo Pink Sheet technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Xvivo Perfusion AB. In general, you should focus on analyzing Xvivo Pink Sheet price patterns and their correlations with different microeconomic environments and drivers.
Xvivo Perfusion Predictive Forecast Models
Xvivo Perfusion's time-series forecasting models is one of many Xvivo Perfusion's pink sheet analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Xvivo Perfusion's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the pink sheet market movement and maximize returns from investment trading.
Things to note about Xvivo Perfusion AB
Checking the ongoing alerts about Xvivo Perfusion for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Xvivo Perfusion AB help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Xvivo Perfusion AB generated a negative expected return over the last 90 days | |
| Xvivo Perfusion AB has accumulated about 22.66 M in cash with (12.06 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.86. | |
| Roughly 12.0% of the company outstanding shares are owned by insiders | |
| Latest headline from MacroaxisInsider: Acquisition by Hankey Bret of 1063830 shares of Bone Biologics subject to Rule 16b-3 |
Other Information on Investing in Xvivo Pink Sheet
Xvivo Perfusion financial ratios help investors to determine whether Xvivo Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Xvivo with respect to the benefits of owning Xvivo Perfusion security.